Overview

A Compassionate Use Protocol of AMX0035 for Treatment of Patients With Amyotrophic Lateral Sclerosis (ALS)

Status:
Enrolling by invitation
Trial end date:
2023-01-01
Target enrollment:
Participant gender:
Summary
The protocol is intended to provide extended treatment with AMX0035 to patients who previously participated in an Amylyx sponsored study of AMX0035 for ALS.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Amylyx Pharmaceuticals Inc.